{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Catalano M"],"pubmed_abstract":["<h4>Background</h4>Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia in pretreated RCC patients with BMs receiving immunotherapy.<h4>Materials and methods</h4>This retrospective multicenter study included RCC patients with BMs receiving nivolumab as second-line therapy or beyond. Inclusion criteria involved baseline sodium levels (pre-ICI) and sodium levels after 4 weeks of nivolumab initiation (post-ICI). The population was divided into two groups based on the median value, and response rates, progression-free survival (PFS), and overall survival (OS) were assessed.<h4>Results</h4>Among 120"],"journal":["Frontiers in immunology"],"pagination":["1361010"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11257879"],"repository":["biostudies-literature"],"pubmed_title":["Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study."],"pmcid":["PMC11257879"],"pubmed_authors":["Maruzzo M","Morelli F","Rebuzzi SE","Roviello G","Naglieri E","Catalano M","Pipitone S","De Giorgi U","Prati G","Zampiva I","Banna GL","Chiellino S","Buti S","Galli L","Mollica V","Ricotta R","Prati V","Atzori F","Di Napoli M","Antonuzzo L","Nole F","Fornarini G","Claps M","Rescigno P","Cerbone L","Soraru M","Fratino L","Zucali PA","Vignani F","Caffo O","Tudini M","Signori A","Cavo A","Malgeri A"],"additional_accession":[]},"is_claimable":false,"name":"Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.","description":"<h4>Background</h4>Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia in pretreated RCC patients with BMs receiving immunotherapy.<h4>Materials and methods</h4>This retrospective multicenter study included RCC patients with BMs receiving nivolumab as second-line therapy or beyond. Inclusion criteria involved baseline sodium levels (pre-ICI) and sodium levels after 4 weeks of nivolumab initiation (post-ICI). The population was divided into two groups based on the median value, and response rates, progression-free survival (PFS), and overall survival (OS) were assessed.<h4>Results</h4>Among 120","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T01:18:52.856Z","creation":"2025-04-04T01:18:52.856Z"},"accession":"S-EPMC11257879","cross_references":{"pubmed":["39034992"],"doi":["10.3389/fimmu.2024.1361010"]}}